A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Trofinetide (Primary)
  • Indications Rett syndrome
  • Focus Adverse reactions; Proof of concept
  • Sponsors Neuren Pharmaceuticals
  • Most Recent Events

    • 24 Jun 2016 According to a Neuren media release, the European Union has granted Orphan Drug designation to trofinetide for the treatment of Rett syndrome.
    • 24 Jun 2016 According to a Neuren media release, the company announced development program of trofinetide for the treatment of Rett syndrome at the Rettsyndrome.org 2016 Research Symposium.
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top